Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion

Seoul National University Hospital

Overview

The aim of this study is to compare the efficacy of transarterial chemoembolization with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion with cisplatin combination in advanced hepatocellular carcinoma with portal vein invasion.

Potentially curative treatments for hepatocellular carcinoma (HCC) include surgical resection, liver transplantation, and local ablative therapy. However, HCC patients are diagnosed at advanced stages in Korea. Especially, HCCs with portal vein invasion are unresectable and they are not suitable for other curative therapies. For these patients, the optimal treatment remains largely controversial. As a palliative treatment, the benefit of transarterial chemoembolization (TACE) had been shown in patients with unresectable HCC and without portal vein invasion by several trials. In patients with main portal vein invasion, TACE is theoretically contraindicated because of the potential risk of hepatic failure resulting from ischemia after TACE. However, recent studies have revealed that TACE could safely be performed in these patients. The aim of this study is to compare the efficacy of transarterial chemoembolization (TACE) with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion (TACI) with cisplatin combination in advanced hepatocellular carcinoma with portal vein invasion.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Hepatocellular Carcinoma

Interventions

DoxorubicinDRUG

Transarterial chemoembolization (TACE) with adriamycin

CisplatinDRUG

transarterial chemoinfusion with cisplatin 50-100 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with clinical or histological diagnosis of HCC based on the guidelines of the AJCC * Patients with advanced HCC with invasion of major branch(es) of portal vein in the arterial phase of dynamic CT or MRI * Patients who have received previous local therapy treatments (RFA, PEI, cryoablation, surgery, resection) are eligible * Age : 18 years to 80 years * ECOG Performance Status of 0 to 2 * Child-Pugh class A (Child-Pugh score 5-6) * Adequate bone marrow, liver function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: * WBC count \> 2,000/mm3 * Absolute neutrophil count \> 1,000/mm3 * Hb ≧ 8.0 g/dL * Platelet count ≧ 50,000 /mm3 * Bilirubin ≦ 3 mg/dL * Adequate clotting function: INR \< 2.3 or \< 6sec Exclusion Criteria: * Child-Pugh score ≧ 7 * ECOG Performance Status ≧ 3 * Patients with chronic kidney disease or serum creatinine ≥ 1.2 mg/dL * History of organ allograft * Patients with uncontrolled co-morbidity which needs treatment * Patients who have received prior systemic chemotherapy * Patients with extrahepatic metastasis

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Overall survival

Time frame: every 12 weeks, up to 48 weeks

Secondary Outcomes

Time-to-progression

Time frame: every 12 weeks, up to 48 weeks

Progression-free survival

Time frame: every 12 weeks, up to 48 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.